Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background and Aims</h3><p>Little is known about EBV-associated intrahepatic cholangiocarcinoma (EBVaICC) due to its rarity. We aimed to comprehensively investigate the clinicopathology, tumor immune microenvironment (TIME) and genomic landscape of this entity in southern China.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We evaluated 303 ICCs using <em>in situ</em> hybridization for EBV, we compared clinicopathological parameters between EBVaICC and nonEBVaICC, and we analyzed EBV infection status, tumor-infiltrating lymphocytes (TILs) and genomic features of EBVaICC by immunohistochemistry, double staining, nested PCR, multiplex immunofluorescence staining, fluorescence <em>in situ</em> hybridization and whole exome sequencing.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>EBVaICC accounted for 6.6% of ICCs, with EBV latency type I infection and clonal EBV isolates form. Distinctive clinicopathological characteristics of EBVaICC included female predominance, younger patient predominance, solitary tumor, higher HBV infection rate, lower cirrhotic background and increased lymphoepithelioma-like (LEL) subtype proportion. EBVaICC had a significantly larger TIME component than nonEBVaICC. The LEL subtype of EBVaICC, which had a significantly increased density and proportion of CD20+ B cells and CD8+ T cells, was significantly related to longer 2-year OS and RFS than EBVaICC conventional type and nonEBVaICC. Both PD-1 and PD-L1 in TILs and PD-L1 in tumor cells were overexpressed in EBVaICC. Tumor microenvironment immune type (TMIT) I (PDL1-Tumor+/CD8<sup>-High</sup>) was significantly more common in EBVaICC than in nonEBVaICC. Mutated genes in at least three cases, including <em>MUC4</em>, <em>DNAH1, GLI2</em>, <em>LIPE</em>, <em>MYH7</em>, <em>RP11-766F14.2</em> and <em>WDR36</em>, were uncovered. EBVaICC had different mutational pattern compared with reported liver fluke-associated cholangiocarcinoma and HBV-associated ICC.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>EBVaICC, as a subset of ICC, has unique etiological characteristics, clinicopathology and molecular genetics with a significantly larger TIME component. Most cases belong to TMIT I. Paradoxically, patients with EBVaICC could be candidates for immune checkpoint therapy.</p>

Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma

Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.

Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report

PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review

Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis

Activated Interferon-Γ (Ifn-Γ) Pathway Associated with Clinical Benefit to Programmed Cell Death Protein-1 (PD-1)/PD Ligand 1 (Pd-L1)-based Therapy in Esophageal Squamous Cell Carcinoma (ESCC).

Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma

Safety and Efficacy of Anti-Pd-1 Inhibitors in Chinese Patients with Advanced Lung Cancer and Hepatitis B Virus Infection: a Retrospective Single-Center Study

Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients

Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications

Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study

Association of B Cells in Tumor Microenvironment (TME) with Clinical Benefit to Programmed Cell Death Protein-1 (PD-1) Blockade Therapy in Esophageal Squamous Cell Carcinoma (ESCC).

A Metastatic Intrahepatic Cholangiocarcinoma Treated with Programmed Cell Death 1 Inhibitor: a Case Report and Literature Review

Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein–Barr virus-associated gastric cancer

PD-1 Inhibitors Plus Chemotherapy for Refractory EBV-positive DLBCL: a Retrospective Analysis

PD-1/PD-L1 Expression Profiles Within Intrahepatic Cholangiocarcinoma Predict Clinical Outcome

Positive Status of Epstein-Barr Virus As a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study

Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors

Lymphocytes in Patients with Chronic Active Epstein-Barr Virus Disease Exhibited Elevated PD-1/PD-L1 Expression and a Prevailing Th2 Immune Response

CRISPR-Cas9-mediated Disruption of PD-1 on Human T Cells for Adoptive Cellular Therapies of EBV Positive Gastric Cancer.

Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer